Form 4: United Therapeutics Exec Sells Shares Under 10b5-1 Plan

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp, reported transactions involving the acquisition and disposition of common stock and stock options on April 8, 2026, executed under a pre-arranged 10b5-1 trading plan.

Summary

• Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp, engaged in a series of transactions on April 8, 2026.
• These transactions included the exercise of stock options and the subsequent sale of common stock.
• A total of 9,500 shares were acquired through option exercise at a price of $146.03 per share.
• Following the exercise, a total of 9,500 shares were sold at various prices, with a weighted average price reported.
• The reporting person also disposed of a significant number of shares through multiple sales transactions, with prices ranging from $564.97 to $586.01.
• These sales resulted in a decrease in directly held common stock.
• The transactions were conducted under a Rule 10b5-1 trading plan adopted on November 7, 2025, which is set to continue until the exercise of 1,734,410 stock options (expiring March 17, 2027) or December 31, 2026, whichever comes first.
• Beneficial ownership also includes shares held indirectly through family trusts and by a spouse.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral. While it involves significant share sales by a key executive, the transactions were conducted under a pre-established 10b5-1 plan, indicating a structured and compliant approach rather than opportunistic selling.

Positives

• The exercise of stock options and subsequent sale of shares were executed under a pre-arranged 10b5-1 trading plan, indicating adherence to established compliance procedures.
• The plan allows for orderly disposition of shares, potentially mitigating market impact.
• The reporting person retains significant beneficial ownership through various trusts and direct holdings.

Negatives

• A substantial number of shares were sold by a key executive, which could be perceived negatively by the market.
• The weighted average sale price for a significant portion of the disposed shares was considerably higher than the option exercise price, indicating a substantial profit realization.

Risks

• The ongoing 10b5-1 plan involves the potential exercise and sale of a large number of stock options, which could lead to further dilution or selling pressure if exercised and sold.
• The plan's continuation is contingent on the exercise of options, which are subject to expiration.

Future Outlook

The 10b5-1 trading plan is active and will continue until December 31, 2026, or until 1,734,410 stock options are exercised, whichever occurs first. This plan governs future transactions of stock options and common stock by the reporting person.

Management Comments

• The exercise of stock options and sale of resulting shares were pursuant to a pre-arranged 10b5-1 trading plan.
• The reporting person undertakes to provide full information regarding the number of shares and prices at which transactions were effected upon request.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The use of a 10b5-1 plan by a CEO of a biotech/pharma company like United Therapeutics is common practice to manage personal stock holdings while adhering to insider trading regulations, especially when dealing with significant option grants.

Stakeholder Impact

• Shareholders: The sale of shares by the CEO, even under a 10b5-1 plan, may lead to short-term market perception concerns, although the plan itself is designed to mitigate negative impacts.
• Employees: The exercise and sale of options by management can be seen as a signal of confidence in the company's future, but also represents a realization of value by insiders.
• Creditors: No direct impact is indicated.

Next Steps

• The 10b5-1 trading plan will continue until December 31, 2026, or until 1,734,410 stock options are exercised.
• Future transactions under the plan will be reported on subsequent Form 4 filings.

Key Dates

Keywords

Form 4, SEC Filing, United Therapeutics, UTHR, Stock Options, Common Stock, Insider Trading, 10b5-1 Plan, Martine Rothblatt, Beneficial Ownership, Securities Transaction